文献速递呼吸危重症与机械通气呼吸道感染

术后持续气道正压预防腹部大手术后肺炎、再插管和死亡(PRISM):多中心开放标签随机3期试验

Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial.
PubMed 文献 · Lancet Respir Med · 2021-06-18

PRISM试验在6国70家医院纳入4806例≥50岁择期腹部大手术患者,随机分为术后4小时内CPAP组或常规术后护理组。

要点

  • 术后预防性CPAP未降低腹部大手术后30天内肺炎、再插管或死亡复合终点。
  • 尽管CPAP可用于术后呼吸衰竭治疗,但不推荐常规预防性术后使用。

核心结论

  • 在大型临床实效试验中,术后CPAP未减少腹部大手术后肺炎、气管再插管或死亡的发生率。
  • 尽管CPAP在术后呼吸衰竭治疗中有重要作用,不推荐常规预防性术后使用CPAP。

研究设计与样本

  • PRISM为开放标签、随机、3期试验,在6个国家70家医院进行。
  • 纳入≥50岁择期腹部大开放手术患者,随机1:1分配至术后4小时内开始CPAP组或常规术后护理组。
  • 共4806例随机(CPAP组2405例,常规组2401例),主要分析纳入4793例(CPAP组2396例,常规组2397例)。
  • 主要终点为随机后30天内肺炎、气管再插管或死亡的复合终点,在意向治疗人群中评估。

主要发现

  • 严重不良事件2例:1例显著听力丧失,1例CPAP头罩导致静脉导管阻塞引起短暂血流动力学不稳定。

临床怎么用

  • 不推荐在腹部大手术后常规预防性使用CPAP以预防肺炎、再插管或死亡。
  • CPAP仍可用于术后呼吸衰竭的治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Respiratory complications are an important cause of postoperative morbidity. We aimed to investigate whether continuous positive airway pressure (CPAP) administered immediately after major abdominal surgery could prevent postoperative morbidity. METHODS: PRISM was an open-label, randomised, phase 3 trial done at 70 hospitals across six countries. Patients aged 50 years or older who were undergoing elective major open abdominal surgery were randomly assigned (1:1) to receive CPAP within 4 h of the end of surgery or usual postoperative care. Patients were randomly assigned using a computer-generated minimisation algorithm with inbuilt concealment. The primary outcome was a composite of pneumonia, endotracheal re-intubation, or death within 30 days after randomisation, assessed in the intention-to-treat population. Safety was assessed in all patients who received CPAP. The trial is registered with the ISRCTN registry, ISRCTN56012545. FINDINGS: Between Feb 8, 2016, and Nov 11, 2019, 4806 patients were randomly assigned (2405 to the CPAP group and 2401 to the usual care group), of whom 4793 were included in the primary analysis (2396 in the CPAP group and 2397 in the usual care group). 195 (8·1%) of 2396 patients in the CPAP group and 197 (8·2%) of 2397 patients in the usual care group met the composite primary outcome (adjusted odds ratio 1·01 [95% CI 0·81-1·24]; p=0·95). 200 (8·9%) of 2241 patients in the CPAP group had adverse events. The most common adverse events were claustrophobia (78 [3·5%] of 2241 patients), oronasal dryness (43 [1·9%]), excessive air leak (36 [1·6%]), vomiting (26 [1·2%]), and pain (24 [1·1%]). There were two serious adverse events: one patient had significant hearing loss and one patient had obstruction of their venous catheter caused by a CPAP hood, which resulted in transient haemodynamic instability. INTERPRETATION: In this large clinical effectiveness trial, CPAP did not reduce the incidence of pneumonia, endotracheal re-intubation, or death after major abdominal surgery. Although CPAP has an important role in the treatment of respiratory failure after surgery, routine use of prophylactic post-operative CPAP is not recommended. FUNDING: National Institute for Health Research, Barts Charity, Intersurgical, Association of Anaesthetists, and Sapienza Università di Roma.

来源:Lancet Respir Med,查看原文。版权归原作者所有。

引用

  1. Postoperative continuous positive airway pressure to prevent pneumonia, re-intubation, and death after major abdominal surgery (PRISM): a multicentre, open-label, randomised, phase 3 trial. Lancet Respir Med. 2021. PMID: 34153272. doi:10.1016/S2213-2600(21)00089-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。